HOUSTON and SAN DIEGO, Nov. 11, 2024
TAC01-CLDN18.2 was well tolerated, with no dose-limiting toxicities and a favorable safety profile in the first two cohorts of the ongoing trial
Advertisement
A pancreatic cancer patient treated with the lowest dose has demonstrated clinical benefit for nearly eight months and achieved a confirmed partial response in the target lesion as well as an unconfirmed complete response in the non-target lesion
Advertisement
HOUSTON and SAN DIEGO, Nov. 11, 2024 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that preliminary results from its Phase I/II clinical trial TACTIC-3 (NCT05862324) investigating the safety and efficacy of autologous TAC01-CLDN18.2 in subjects with Claudin 18.2 positive solid tumors, were presented in a poster and an oral presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting, held November 6-10 in Houston.
Ecaterina E. Dumbrava, MD, Assistant Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, presented promising preliminary clinical data from TACTIC-3 showing the positive safety profile and encouraging therapeutic potential of TAC01-CLDN18.2 at lower dosages, even among patients who have undergone multiple prior treatments. Dr. Dumbrava's late-breaking abstract was selected for an oral presentation during the "Biotech Breakthroughs - Solid Tumor IO at the Tipping Point" session on Friday, November 8, and displayed during a Poster session on Saturday, November 9.
"As an emerging biomarker, Claudin 18.2 offers a promising target for cellular therapies due to its selective expression in certain advanced solid tumors, including, but not limited to, gastric and pancreatic cancers," said Dr. Dumbrava. "These initial data on TAC01-CLDN18.2, a new T-cell therapy approach designed to address the needs of patients with solid tumors expressing Claudin 18.2 are promising. Because this is a patient population with limited treatment choices, I look forward to the full results of the clinical trial TAC01-CLDN18.2's potential to improve patient outcomes."
Key Preliminary Findings
Oral Presentation Details:
Title: A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors
Authors: Ecaterina E. Dumbrava, Syma Iqbal, Simon Turcotte, Gregory Botta, Benjamin Schlechter, Geoffrey Ku, Peter Hosein, Sam Saibil, Miriam Gavriliuc, Maria Apostolopoulou, Mobolaji Giwa, Kara Moss, Swaminathan Murugappan, Davendra Sohal
Session: Biotech Breakthroughs - Solid Tumor IO at the Tipping Point
Oral Presentation Date: Friday, November 8, 2024, between 1:45 p.m. and 3:20 p.m. CDT
Abstract Number: 1472
Abstract Type: Late-Breaking Abstract
Abstracts are currently available on the SITC website.
About Triumvira Immunologics
Triumvira Immunologics, Inc. ("Triumvira") is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology platform activates natural T cell functions differently from other cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies, resulting in clinically safe, effective, and re-dosable cell therapies. Triumvira is developing a pipeline targeting promising tumor-associated antigens such as Claudin 18.2, HER2, GUCY2C and GPC3. Triumvira has operations in San Diego, CA, Austin, Texas, and Hamilton, Ontario.
For more information, visit us at www.triumvira.com or follow us on LinkedIn and X.
Media ContactDavid Schull or Ignacio Guerrero-Ros, Ph.D.Russo Partners858-717-2310646-942-5604david.schull@[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/triumvira-immunologics-late-breaking-abstract-selected-for-oral-presentation-at-the-39th-sitc-annual-meeting-demonstrates-preliminary-safety-and-promising-clinical-activity-of-tac01-cldn18-2-cell-therapy-in-patients-with-solid-tu-302301785.html
SOURCE Triumvira Immunologics
